NASDAQ:APTX Aptinyx (APTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.09▼$0.1050-Day Range$0.06▼$0.1052-Week Range$0.01▼$0.72Volume231,100 shsAverage Volume1.32 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aptinyx alerts: Email Address Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Aptinyx Stock (NASDAQ:APTX)Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Read More Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> APTX Stock News HeadlinesApril 23, 2024 | businesswire.comTentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEOMarch 12, 2024 | benzinga.comNew Leaf Venture Management III, L.L.C.'s Net WorthJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...February 9, 2024 | benzinga.comPatrick J Heron's Net WorthJanuary 13, 2024 | cnet.comBest Noise-Canceling Headphones for 2024December 17, 2023 | morningstar.comAptinyx Inc APTXSeptember 7, 2023 | morningstar.comNorth American Morning Briefing: Concerns About -2-March 30, 2023 | finance.yahoo.comHere's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock NowJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...February 27, 2023 | finance.yahoo.comAptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate UpdateJanuary 31, 2023 | finance.yahoo.comAptinyx to Present at the SVB Securities Global Biopharma ConferenceJanuary 16, 2023 | ca.finance.yahoo.comAptinyx Inc. (APTX) Stock Historical Prices & Data - Yahoo FinanceJanuary 5, 2023 | fool.comAptinyx (NASDAQ: APTX)December 30, 2022 | insidermonkey.comAptinyx Inc. (NASDAQ:APTX) Q3 2022 Earnings Call TranscriptDecember 12, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)November 8, 2022 | finance.yahoo.comAptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsOctober 30, 2022 | fool.comAptinyx Inc. (NASDAQ: APTX)October 18, 2022 | finance.yahoo.comAptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022See More Headlines Receive APTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APTX CUSIPN/A CIK1674365 Webwww.aptinyx.com Phone(847) 871-0377FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book0.17Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 61)Principal Executive Officer, Fin. & Accounting Officer, President, Treasurer, Secretary and Director Mr. Patrick FlavinSenior Manager of Corporate Development & Investor RelationsMs. Molly DirVice President of Human ResourcesDr. Kathryn King Ph.D.Senior Vice President of Clinical & CMC OperationsMr. Tim NoffkeVP of Program Management & Chief of StaffDr. Harald Murck M.D.Ph.D., Vice President of Clinical & Medical AffairsMore ExecutivesKey CompetitorsAesther Healthcare AcquisitionNASDAQ:AEHAWBioLingus (Cayman)NASDAQ:SUBLEvelo BiosciencesNASDAQ:EVLOGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXView All Competitors APTX Stock Analysis - Frequently Asked Questions How were Aptinyx's earnings last quarter? Aptinyx Inc. (NASDAQ:APTX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). When did Aptinyx IPO? Aptinyx (APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB) and Cidara Therapeutics (CDTX). This page (NASDAQ:APTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptinyx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptinyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.